These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Yin Y; Yuan H; Wang C; Pattabiraman N; Rao M; Pestell RG; Glazer RI Mol Endocrinol; 2006 Feb; 20(2):268-78. PubMed ID: 16150867 [TBL] [Abstract][Full Text] [Related]
5. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes. Li G; Leff T Mol Endocrinol; 2007 Apr; 21(4):857-64. PubMed ID: 17227883 [TBL] [Abstract][Full Text] [Related]
6. [PPARgamma variants and complex diseases]. Ji SL; Huang QY Yi Chuan; 2006 Aug; 28(8):993-1001. PubMed ID: 16870588 [TBL] [Abstract][Full Text] [Related]
7. Studies of liver tissue identify functional gene regulatory elements associated to gene expression, type 2 diabetes, and other metabolic diseases. Cavalli M; Baltzer N; Pan G; Bárcenas Walls JR; Smolinska Garbulowska K; Kumar C; Skrtic S; Komorowski J; Wadelius C Hum Genomics; 2019 Apr; 13(1):20. PubMed ID: 31036066 [TBL] [Abstract][Full Text] [Related]
8. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists. Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518 [TBL] [Abstract][Full Text] [Related]
9. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus. Shiraki T; Kodama TS; Jingami H; Kamiya N Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556 [TBL] [Abstract][Full Text] [Related]
10. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Wu LS; Hsieh CH; Pei D; Hung YJ; Kuo SW; Lin E Nephrol Dial Transplant; 2009 Nov; 24(11):3360-6. PubMed ID: 19506043 [TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Andrulionyte L; Peltola P; Chiasson JL; Laakso M; Diabetes; 2006 Jul; 55(7):2148-52. PubMed ID: 16804087 [TBL] [Abstract][Full Text] [Related]
12. Quantitative candidate gene association studies of metabolic traits in Han Chinese type 2 diabetes patients. Wei FJ; Cai CY; Yu P; Lv J; Ling C; Shi WT; Jiao HX; Chang BC; Yang FH; Tian Y; Li MS; Wang YH; Zou L; Shi JM; Chen LM; Li WD Genet Mol Res; 2015 Dec; 14(4):15471-81. PubMed ID: 26634513 [TBL] [Abstract][Full Text] [Related]
13. Genetic Variation Determines PPARγ Function and Anti-diabetic Drug Response In Vivo. Soccio RE; Chen ER; Rajapurkar SR; Safabakhsh P; Marinis JM; Dispirito JR; Emmett MJ; Briggs ER; Fang B; Everett LJ; Lim HW; Won KJ; Steger DJ; Wu Y; Civelek M; Voight BF; Lazar MA Cell; 2015 Jul; 162(1):33-44. PubMed ID: 26140591 [TBL] [Abstract][Full Text] [Related]
14. Functional Screening of Candidate Causal Genes for Insulin Resistance in Human Preadipocytes and Adipocytes. Chen Z; Yu H; Shi X; Warren CR; Lotta LA; Friesen M; Meissner TB; Langenberg C; Wabitsch M; Wareham N; Benson MD; Gerszten RE; Cowan CA Circ Res; 2020 Jan; 126(3):330-346. PubMed ID: 31739742 [No Abstract] [Full Text] [Related]
15. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients. Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824 [TBL] [Abstract][Full Text] [Related]
16. STAT1 and STAT6 Act as Antagonistic Regulators of PPARγ in Diabetic Patients with and without Cardiovascular Diseases. Bendaya I; Riahi A; Kharat M; Kahla S; Sdiri W; Oueslati R Clin Lab; 2018 Mar; 64(3):287-294. PubMed ID: 29739101 [TBL] [Abstract][Full Text] [Related]
17. FTO T/A and peroxisome proliferator-activated receptor-γ Pro12Ala polymorphisms but not ApoA1 -75 are associated with better response to lifestyle intervention in Brazilians at high cardiometabolic risk. Curti ML; Rogero MM; Baltar VT; Barros CR; Siqueira-Catania A; Ferreira SR Metab Syndr Relat Disord; 2013 Jun; 11(3):169-76. PubMed ID: 23438152 [TBL] [Abstract][Full Text] [Related]
18. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes. Mazzucotelli A; Viguerie N; Tiraby C; Annicotte JS; Mairal A; Klimcakova E; Lepin E; Delmar P; Dejean S; Tavernier G; Lefort C; Hidalgo J; Pineau T; Fajas L; Clément K; Langin D Diabetes; 2007 Oct; 56(10):2467-75. PubMed ID: 17646210 [TBL] [Abstract][Full Text] [Related]
19. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes. Kim KY; Cho HS; Jung WH; Kim SS; Cheon HG Mol Pharmacol; 2007 Jun; 71(6):1554-62. PubMed ID: 17337625 [TBL] [Abstract][Full Text] [Related]